Programs

The USCACA and NFCR are pleased to invite nominations for the USCACA-NFCR 2014 Scholar Awards

The Awards will recognize four junior Chinese investigators on the basis of significant contributions in translational cancer research

The Awards will be presented in a ceremony during the 16th Chinese Society of Clinical Oncology (CSCO) annual meeting, September 17-21, 2014, Xiamen, China.

The USCACA and NFCR are pleased to invite nominations for the USCACA-NFCR 2013 Scholar Awards

The Awards will recognize four junior Chinese investigators on the basis of significant contributions in basic and translational cancer research

The Awards will be presented in a ceremony during the 3rd Guangzhou International Symposium on Oncology, November 7-9, 2013, Guangzhou, China.

Purpose
U.S. Chinese Anti-Cancer Association (USCACAÃÀÖп¹¡ã©Ð­»¡§¢)- National Foundation for Cancer Research-USA (NFCR-USA, ¹¡§²¼Ò¡ã©Ö¢»¡§´½ð-ÃÀ¹¡§²) has established the USCACA-NFCR Scholar Award of Clinical, Translational, and Basic Cancer Research. The purpose of this award program is to reward clinicians and basic researchers from China who performed clinical/translational or basic research in cancer under supervision of USCACA members at hospitals or research institutions in the US.

U.S. Chinese Anti-Cancer Association (USCACA，美中抗癌协会) is a non-profit professional organization founded in 2009. With members from academia, industry and government, USCACA facilitates collaboration among cancer researchers and physicians in the United States and China. Our current focus is on expediting novel cancer drug development by fostering clinical trial networks, sharing best practices and knowledge of clinical trial, and providing education and training opportunities between China and United States.

Introduction
The phenomenal expansion of our knowledge in molecular biology of cancer in the last decade has led to an unprecedented number of exciting new targets for cancer treatment. A typical oncology drug candidate has many developmental opportunities as determined by line of therapy and tumor type, making it a hard decision as how to proceed amid uncertainties inherent in preclinical and early clinical data (dosing schedules, combination therapies and existence of a possible response signature further complicates the issue.)